142 related articles for article (PubMed ID: 32285356)
1. Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET.
Antunes IF; Hospers GAP; Sijbesma JWA; Boerema AS; van Waarde A; Glaudemans AWJM; Dierckx RAJO; de Vries EGE; de Vries EFJ
Mol Imaging Biol; 2020 Oct; 22(5):1218-1225. PubMed ID: 32285356
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
4. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Giuliano M; Hu H; Wang YC; Fu X; Nardone A; Herrera S; Mao S; Contreras A; Gutierrez C; Wang T; Hilsenbeck SG; De Angelis C; Wang NJ; Heiser LM; Gray JW; Lopez-Tarruella S; Pavlick AC; Trivedi MV; Chamness GC; Chang JC; Osborne CK; Rimawi MF; Schiff R
Clin Cancer Res; 2015 Sep; 21(17):3995-4003. PubMed ID: 26015514
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
9. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
10. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
[TBL] [Abstract][Full Text] [Related]
11. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract][Full Text] [Related]
12. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B
PLoS One; 2017; 12(5):e0177331. PubMed ID: 28493933
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
14. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
17. Clinical Validity of 16α-[
van Geel JJL; Boers J; Elias SG; Glaudemans AWJM; de Vries EFJ; Hospers GAP; van Kruchten M; Kuip EJM; Jager A; Menke-van der Houven van Oordt WC; van der Vegt B; de Vries EGE; Schröder CP;
J Clin Oncol; 2022 Nov; 40(31):3642-3652. PubMed ID: 35584346
[TBL] [Abstract][Full Text] [Related]
18. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
[TBL] [Abstract][Full Text] [Related]
19. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[
Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
[TBL] [Abstract][Full Text] [Related]
20. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
